Logo
x

Search

Subscribe Now

HUTCHMED

HUTCHMED’ Orpathys (Savolitinib) Receives the NMPA’s Full Approval for Locally Advanced or Metastatic MET Exon 14 NSCLC

HUTCHMED’ Orpathys (Savolitinib) Receives the NMPA’s Full Approval for Locally Advanced or Metastatic MET Exon 14 NSCLC

  • January 15, 2025
HUTCHMED Reports the NMPA’s NDA Acceptance of Orpathys Plus Tagrisso with Priority Review for EGFR-Mutated NSCLC with MET Amplification

HUTCHMED Reports the NMPA’s NDA Acceptance of Orpathys Plus Tagrisso with Priority Review for EGFR-Mutated NSCLC with MET Amplific...

  • January 2, 2025
HUTCHMED Secures $10M Milestone Payment from Takeda Following the First Reimbursement of Fruzaqla in Europe

HUTCHMED Secures $10M Milestone Payment from Takeda Following the First Reimbursement of Fruzaqla in Europe

  • December 13, 2024
HUTCHMED’s Orpathys and Tagrisso Combination Secures the NMPA’s Breakthrough Therapy Designation for Lung Cancer

HUTCHMED’s Orpathys and Tagrisso Combination Secures the NMPA’s Breakthrough Therapy Designation for Lung Cancer

  • December 12, 2024
HUTCHMED and Innovent Report the NMPA’s Conditional Approval of Elunate Plus Tyvyt to Treat Advanced Endometrial Cancer

HUTCHMED and Innovent Report the NMPA’s Conditional Approval of Elunate Plus Tyvyt to Treat Advanced Endometrial Cancer

  • December 3, 2024
HUTCHMED Reports the NMPA’s NDA Acceptance of Tazemetostat for Treating Follicular Lymphoma

HUTCHMED Reports the NMPA’s NDA Acceptance of Tazemetostat for Treating Follicular Lymphoma

  • July 4, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.